氯喹在新冠肺炎治疗过程中的安全性  

Safety Review of Chloroquine in the Treatment of COVID-19

作　　者：周波[1] 简凤璧[1] 张婧[1] 洪文昕[2] 刘艳清[1] 汪明 张复春[2] 李凌华[2] ZHOU Bo;JIAN Fengbi;ZHANG Jing;HONG Wenxin;LIU Yanqing;WANG Ming;ZHANG Fuchun;LI Linghua(Department of Pharmacy,Guangzhou Eighth People's Hospital,Guangzhou Medical University,Guangzhou,Guangdong 510060,China;Infectious Diseases Centre,Guangzhou Eighth People's Hospital,Guangzhou Medical University,Guangzhou,Guangdong 510060,China)

机构地区：[1]广州市医科大学附属市八医院,广州市第八人民医院药剂科,广东广州510060 [2]广州市医科大学附属市八医院,广州市第八人民医院感染病治疗中心,广东广州510060

出　　处：《今日药学》2021年第3期211-214,218,共5页Pharmacy Today

摘　　要：目的分析氯喹在治疗新型冠状病毒肺炎过程中的安全性,为临床用药提供参考依据。方法分析2020年2月5日~5月5日在广州市第八人民医院使用氯喹治疗新型冠状肺炎的患者中出现不良事件的情况,对用量、合并症、过敏史等数据进行分析统计。结果共纳入112名患者,其中55名患者(49.11%)在使用氯喹期间出现了62例次的不良事件。氯喹用药最短1 d,最长16 d,平均(4.63±2.75)d,62.9%的不良事件发生在前4天,有1例3级的精神系统严重不良事件发生。低剂量组和标准剂量组不良事件主要涉及的器官或系统为消化系统和心脏系统,两组药品不良事件发生率无显著差异,但标准剂量组的心脏系统相关的不良事件发生率更高。结论试用氯喹治疗新冠肺炎时,不良事件的发生率较高,因此,必须谨慎试用氯喹,临床药师应尽早干预和监测用药,以避免不当给药,确保治疗安全。OBJECTIVE To analyze the safety of chloroquine(CQ)in the treatment of COVID-19 and provide references for clinical medication.METHODS The medical recordsobtained from Guangzhou Eighth People's Hospital were reviewed to extract data about patients who received CQ phosphate tablets for COVID-19 treatment from February 5 to May 5,2020.The data of dosage,complications,allergic history were assessed to determine the correlation between adverse events(ADEs)with CQ and the severity of ADEs.RESULTS A total of 112 patients were included in this study,55 patients(49.11%)experienced 62 ADEs.Chloroquine was administered for a minimum of 1 day and a maximum of 16 days,with an average of(4.63±2.75)days,and 62.9%of the ADEs were occurred in the first 4 days of treatment.Among the ADEs,there was a level 3 ADE occurred which damaged mental system.ADEs mainly were occurred in the digestive and cardiac systems in both low-dose and standard-dose groups.The two treatments did not significantly affect the incidence of ADEs,but the incidence of adverse events related to the cardiac system was higher in the standarddose group.CONCLUSION This review demonstrated a high incidence of ADEs for treating COVID-19 with oral CQ.Thus,caution must be exercised while utilizing CQ for pharmaceutical care,and clinical pharmacists should intervene and monitor the use of CQ as soon as possible to avoid improper administration and ensure safety.

关 键 词：氯喹 安全性 不良事件 新型冠状病毒肺炎 

分 类 号：R969[医药卫生—药理学]